RED CELL PATHOLOGY UNIT. HOSPITAL CLINIC-UNIVERSITY OF BARCELONA, Spain

Similar documents
The Centre for Disease Prevention and Control, Latvia

National Center for Tumor Diseases (NCT) Heidelberg, Germany

Central Manchester University Hospitals NHS Foundation Trust, UK

Hospital Universitario de Getafe (Getafe Universitary Hospital), Spain

Hospital Carlos Haya. Malaga, Spain

Department of Medical Genetics, Medical School, University of Athens, Greece

INSTITUTE OF CHILD HEALTH, Greece

Ministry for Health, the Elderly and Community Care, Malta

European Society of Cardiology, France

Radboud University Nijmegen Medical Centre, department of Neurology, Netherlands

SERVICIO DE NEUROCIRUGÍA PEDIÁTRICA. HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, Spain

Scandinavian Ear Reconstruction Centre, Dept of Plastic and Reconstructive Surgery, SWEDEN

Erasmus MC, Center for lysosomal and metabolic diseases, Netherlands

Riga East University hospital stationary Infectology Center of Latvia (RAKUS LIC), Latvia

Schoen Kliniken group, Schoen Klinik Hamburg Eilbek, Dept. of neurology and. neurorehabilitation, Germany

Castilla y leon Regional Health Service (Gerencia Regional de Salud de Castilla y León)

Cystic Fibrosis Europe (CFE), Germany

VSOP, Lupus Netherlands

ERN board of Member States

European Haemophilia Consortium

2nd European Reference Networks Conference 8-9 October Lisbon, Portugal. A report by: G Porto & F Courtois

EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES

Developing a European Registry for Rare Anaemias

UNION EUROPÉENNE DES MÉDECINS SPÉCIALISTES

EUCERD RECOMMENDATIONS on RARE DISEASE EUROPEAN REFERENCE NETWORKS (RD ERNS)

European Reference Networks (ERN) Guide for patient advocates

WORK PLAN 2017 LAURENCE BALLIEUX NATIONAL FOCAL POINT. 1 EU 3rd HEALTH PROGRAMME

European Reference Networks. Guidance on the recognition of Healthcare Providers and UK Oversight of Applications

National Plans for Rare Diseases The French plan Ségolène Aymé Orphanet On behalf of Alexandra Fourcade French Ministry of Health

BELGIAN EU PRESIDENCY CONFERENCE ON RHEUMATIC AND MUSCULOSKELETAL DISEASES (RMD)

116 Help Lines for Rare Diseases

FP7: Marie Curie Actions

A short paper for ENVI & IMCO MEPs Two solutions to improve recognition of specialisms in the Chapter III professions

Healthcare Science Assistant

CaixaImpulse Form 2017

European Reference Networks: strategic value for the Member States. Perspective of France

The European network evaluation of the PHAR QA framework of competences for...

ERN Assessment Manual for Applicants 2. Technical Toolbox for Applicants

Joint R&D Support Office SOP S-2011 UHL

EUCERD Joint Action WP7 Workshop From Centres of Expertise for Rare Diseases to European Reference Networks

Do terms like FP6, CORDIS, Specific Programme, Call for

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL. Report on the interim evaluation of the «Daphne III Programme »

ERN Assessment Manual for Applicants

Hospital Pharmacists making the difference in medication use

The clinical scientist in pathology. March 2005

The Seventh Framework Programme for candidate and potential candidate countries European Regional Economic Forum Nova Gorica, 30 May 2007

QUICK REFERENCE TO CALDICOTT & THE DATA PROTECTION ACT 1998 PRINCIPLES

Building the Europe of Knowledge

JOB DESCRIPTION 1 Job Title 2 Location 3 Record Filename. Medical Scientist Haematology Laboratory MF-HAE-JD-03

Delegations will find below the above-mentioned Council conclusions, as endorsed by the Council (General Affairs) on 14 September 2015.

The British Society of Haematology and NIHR Clinical Research Network Award scheme to recognise NHS consultants and trainees active in research

Guideline for Applicants. Intramural Research Funding Programs Faculty of Medicine Tübingen

Member webinar: What is an ideal European Reference Network? Matt Johnson, EURORDIS 10 February 2016

Policies contributing to Health Reforms leading to improved management of Rare Diseases/ Anaemias/ Haemoglobin Disorders in Europe

ehealth in caring for people with multimorbidity in European countries

Council, 25 September 2014

Practice Placement Learning Opportunities/Experiences (NURSING)

Call for Nominations. CARLOS V European Award

A European workforce for call centre services. Construction industry recruits abroad

Implementing the 3rd Health Programme. Ingrid Keller Coordinator Health Programme Consumer, Health and Food Executive Agency

Cross Border Health: ERN-EuroBloodNet s overview for reaching equal access to care across EU MS

ANNEX I TO VIII ANNEX I. Health Programme Work Programme for 2017

Copernicus Incubation Programme

ERC Grant Schemes. Horizon 2020 European Union funding for Research & Innovation

Regional Ministry of Health Mental Health Programme Public Health Service, Regional Ministry of Health from the Government of Andalusia / Spain

Background paper. Cross-border healthcare in the EU

Document: Report on the work of the High Level Group in 2006

Presenting the European Investment Advisory Hub Annual Forum of the EUSDR, 2015 Ulm. European Investment Advisory Hub 1

Call text. The Programme supports 6 fellows working on projects of a duration up to 36 months recruited in the current call for proposals.

European Quality Assurance Scheme for Breast Cancer Services

Current and future standardization issues in the e Health domain: Achieving interoperability. Executive Summary

MARIE SKŁODOWSKA-CURIE ACTIONS. Individual Fellowships (IF) Date: in 12 pts. David WIZEL Research Executive Agency. 18 March 2016 Split

1. Have you or a member of your family had first-hand experience of an adverse event or experienced harm in a healthcare setting in your country?

APPENDIX ONE. ICAT: Integrated Clinical Assessment Tool

Summary of a Survey on the Europe 2020 Flagship Initiative Innovation Union. Executive Summary

JOB DESCRIPTION DIRECTOR OF SCREENING. Author: Dr Quentin Sandifer, Executive Director of Public Health Services and Medical Director

European network of paediatric research (EnprEMA)

Education and Training Committee, 5 June 2014

European Solidarity Corps

How can structured cooperation between countries address health workforce challenges related to highly specialized health care?

Health Select Committee inquiry into Brexit and health and social care

European Investment Advisory Hub

Current trends in European microbiology

Annex 3 Information and Communication Requirements EEA and Norway Grants

ERASMUS+ Erasmus Mundus Joint Master Degrees EMJMDs. Key Action 1. Erasmus+

Health and Social Care

Commissioning Policy (WM12) Patients Changing Responsible Commissioner. Version 2 February 2012

Erasmus+ Work together with European higher education institutions. Piia Heinämäki Erasmus+ Info Day, Lviv Erasmus+

REPOSITIONING OUR CLINICAL LABORATORIES FOR EFFECTIVE AND EFFICIENT HEALTHCARE DELIVERY. By Prof. Ibironke Akinsete Chairman PathCare Nigeria

Simona Bovha, CPCM European Investment Bank. European Investment Advisory Hub

European network of paediatric research (EnprEMA)

Measuring Digital Maturity. John Rayner Regional Director 8 th June 2016 Amsterdam

ERASMUS MUNDUS Frequently-asked questions ACTION 2: Questions from higher education institutions Latest update: January 2011

EFPIA Code of Practice on relationships between the pharmaceutical industry and patient organisations

Call for the expression of interest Selection of six model demonstrator regions to receive advisory support from the European Cluster Observatory

Subject Minutes of the Third Management Committee Meeting of COST Action ES1401 Time Dependent Seismology (TIDES)

Prof Paul Hodiamont Becoming a medical specialist in the Netherlands

The following passage wants to illustrate the insufficiencies in CF care the patients, their families and care giver struggle with:

International dimension of Higher Education 27/06/2015

Training Requirements for the Specialty of Medical Microbiology

Transcription:

RED CELL PATHOLOGY UNIT. HOSPITAL CLINIC-UNIVERSITY OF BARCELONA, Spain 1.1 Please indicate the type of organisation on behalf of which you are responding to this consultation: 1. Respondent Profile Academic/public health and healthcare specialised institution/organisation (e.g. Institutes and University Departments of Public Health, Quality, Healthcare, Clinical Excellence) Please indicate level: National level organisation Please indicate for what the administration is responsible: 1.1.1. Other (please specify): 1.2 Please indicate the name of your organisation or centre: RED CELL PATHOLOGY UNIT. HOSPITAL CLINIC-UNIVERSITY OF BARCELONA 1.3 Please indicate the country where your organsation/centre is located/has its headquarters or main representative office in Europe: 1. Please indicate the number of EU Member States and EEA countries (Norway, Iceland, Lichtenstein) and accessing country (Croatia) in which your organisation conducts business/is represented: 1. If need be, can we contact you by e-mail to obtain further information on your submission? 1..1 Please provide an e-mail address where we can contact you: jlvives@clinic.ub.es ES 1 1.6 Please provide us with a contact person (incl jobtitle and daytime phone number): Prof. Joan-Lluis Vives Corrons (+393190)

1.7 Please provide additional contact details if needed: Mrs. Laura Olaya (laura.olaya@enerca.org) 2. Involvement of your organisation in the matter of centres of excellence/reference (COE) and healthcare networks in highly specialised healthcare (HSHC). 2.1 How would you describe your organisation's knowledge of CoE and HSHC? 2.1.1 Space for further comments: 2.2. What aspects or domains related to the topic of CoE and HSHC would correspond to your organisation's key knowledge? (cross any that applies) Very high Highly specialised healthcare provision Priorities, description and characteristics of CoE and HSHC Ethical analysis Professional performance, clinical practice, quality and safety of specialized healthcare Legal aspects Information system, coding Engineering/e-health 2.2.1. Space for further comments: 2.3 Is highly specialised healthcare a priority in your organisation's strategies and work plans? 2.3.1 Space for further comments: 2.. What specific field of healthcare services/specialities are most relevant for your centre/organisation's field of work? High Laboratories and central services (e.g. pathology, genetics, biochemistry, pharmacy, microbiology etc.) Please specify: National recognised expert centre in rare anaemias

2.. Has your organisation/centre been directly involved in the design or assessment of professional standards and criteria related with highly specialised healthcare? Frequently 2..1 Please describe your role in such actions/projects: European level: Coordination of ENERCA. National Level: Adviser for Haematological diseases in National Plan Regional level: Adviser for the recognition of local Centres of Expertise 2.6. Has your organisation been involved in projects/activities supported by the Commission in relation with HSHC or professional and technical criteria/standards in highly specialised healthcare? 2.7. Do you have concrete examples based on your own organisation's experience or could you provide us with references or links to documents related with professional criteria and standards in highly specialised healthcare/coe or HSHC (e.g. quality criteria, guidelines, consensus documents)? 2.7.1 Space for further comments: Main goal of ENERCA3: Recommendation for the recognition of Centrers of Expertise in Rare Anaemias - ENERCA WHITE BOOK (2013) 2.13. What is the scope of the network? 2.1. Which kind of network? 2.1.1 Space for further comments: 2.1. Would you be interested in applying to the process to be considered Centre of Excellence of the future European Reference Network? (1 = not interested at all, = very interested) 2.1.1 Space for further comments:

3. Proposed criteria for ERN (scope, general and specific criteria) 3.1 Criteria related with diseases or conditions in order to be considered under the scope of the ERN 3.1.1. Need of highly specialised healthcare 3.1.1.1. Complexity of the diagnosis and treatment 3.1.1.2. High cost of treatment and resources 3 3.1.1.3. Need of advanced/highly specialised medical equipment or infrastructures 3.1.2. Need of particular concentration of expertise and resources 3.1.2.1. Rare expertise/need of concentration of cases 3.1.2.2. Low prevalence/incidence/number of cases 3.1.2.3. Evaluated experiences of Member States 3 3.1.3. Based on high-quality, accessible and cost-effective healthcare 3.1.3.1. Evidence of the safety and favourable risk-benefit analysis 3.1.3.2. Feasibility and evidence of the value and potential positive outcome (clinical) 3.1.. Do you recommend any additional criteria or option that would effectively address the issue? No

3.1.. Would you prioritise or suggest any concrete disesase or group of diseases to be addressed by the future ERN according to the above criteria? 3.1..1 Explain your proposal in free text: The rare anaemias group of diseases 3.2. General criteria of the centres wishing to join a European Reference Network 3.2.1. Organisation and management 3.2.2. Patients empowerment and centered care 3.2.3. Patient care, clinical tools and health technology assessment 3.2.. Quality, patient safety and evaluation framework policies 3.2.. Business continuity, contingency planning and response capacity 3.2.6. Information systems, technology and e-health tools and applications 3.2.7. Overall framework and capacity for research and training 3.2.8. Specific commitment of the management/direction of the centre/hospital to ensure a full and active participation in the ERN 3.2.9. Do you recommend any additional option that would effectively address the issue? 3.2.9.1. Space for further comments: No 3.3.1. Competence, experience and good outcomes and care 3.3. Specific criteria regarding the areas of expertise

3.3.2. Specific resources and organisation: 3.3.2.1. Human resources 3.3.2.2. Team/centre organisation 3.3.2.3. Structural conditions 3 3.3.2.. Specific equipment 3.3.2.. Presence and coordination with other required complementary units or services 3.3.3. Patient care pathways, protocols and clinical guidelines in the field of expertise 3.3.. External coordination, care management and follow-up of patients 3.3.. Research, training, health technology assessment in the field of expertise 3.3.6. Specific information systems 3.3.7. Do you recommend any additional criteria or option that would effectively address the issue? 3.3.7.1. Space for further comments: The consideration of ethical and legal issues for each member state